Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Giladi

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Frontiers in Oncology|March 25, 2026
Tumor Treating Fields (TTFields), and their concomitant application with FOLFOX, are effective for the treatment of gastric cancer cellsHila Fishman, Hila M Ene, Einav Zeevi, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
Molecular Cancer Therapeutics|June 30, 2025
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug ResistanceBella Koltun, Tali Voloshin, Cfir David, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical modelsHelena Mumblat, Antonia Martinez-Conde, Ori Braten, et al.
Frontiers in Microbiology|December 14, 2023
Tumor Treating Fields (TTFields) demonstrate antiviral functions <i>in vitro</i>, and safety for application to COVID-19 patients in a pilot clinical studyAvraham Abutbul, Helena Mumblat, Yaara Porat, et al.
Cell Death Discovery|July 10, 2025
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)Kerem Wainer-Katsir, Adi Haber, Hila Fishman, et al.
Cell Death & Disease|March 28, 2025
Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer Tov, et al.
International Journal of Cancer|February 27, 2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxelTal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Mono-allelic p.R37H Dehydrodolichyl Diphosphate Synthase variants lead to protein glycosylation defects, aberrant lipid profiles and interneuron scarcity in a novel mouse model of progressive epileptic encephalopathyAfitz Da Silva, Samuel Boris Tene Tadoum, Irena J J Muffels, et al.
The Journal of Experimental Medicine|February 20, 2025
HMCN1 variants aggravate epidermolysis bullosa simplex phenotypeShir Bergson, Ofer Sarig, Moshe Giladi, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Frontiers in Oncology|March 25, 2026
Tumor Treating Fields (TTFields), and their concomitant application with FOLFOX, are effective for the treatment of gastric cancer cellsHila Fishman, Hila M Ene, Einav Zeevi, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
Molecular Cancer Therapeutics|June 30, 2025
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug ResistanceBella Koltun, Tali Voloshin, Cfir David, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical modelsHelena Mumblat, Antonia Martinez-Conde, Ori Braten, et al.
Frontiers in Microbiology|December 14, 2023
Tumor Treating Fields (TTFields) demonstrate antiviral functions <i>in vitro</i>, and safety for application to COVID-19 patients in a pilot clinical studyAvraham Abutbul, Helena Mumblat, Yaara Porat, et al.
Cell Death Discovery|July 10, 2025
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)Kerem Wainer-Katsir, Adi Haber, Hila Fishman, et al.
Cell Death & Disease|March 28, 2025
Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer Tov, et al.
International Journal of Cancer|February 27, 2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxelTal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
Mono-allelic p.R37H Dehydrodolichyl Diphosphate Synthase variants lead to protein glycosylation defects, aberrant lipid profiles and interneuron scarcity in a novel mouse model of progressive epileptic encephalopathyAfitz Da Silva, Samuel Boris Tene Tadoum, Irena J J Muffels, et al.
The Journal of Experimental Medicine|February 20, 2025
HMCN1 variants aggravate epidermolysis bullosa simplex phenotypeShir Bergson, Ofer Sarig, Moshe Giladi, et al.
Pageof 10